Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 8-20 , March 2009

Drug delivery of siRNA therapeutics: potentials and limits of nanosystems

  • Daniela Reischl, MS
    • ,
  • Andreas Zimmer, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology, Karl-Franzens-University, Schubertstrasse 6, 8010 Graz, Austria.

Received 18 February 2008 ,Accepted 4 June 2008.

References 

  1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498
  2. Fougerolles AD, Manoharan M, Meyers R, Vornlocher HP, Engelke DR, Rossi JJ. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol. 2005;392:278–296
  3. Leung RKM, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther. 2005;107:222–239
  4. Oliveira S, Storm G, Schiffelers R. Targeted delivery of siRNA. J Biomed Biotechnol. 2006;2006:63675
  5. Sharp PA. RNAi and double-strand RNA. Genes Dev. 1999;13:139–141
  6. Caplen N. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 2004;11:1241–1248
  7. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 1990;2:279–289
  8. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811
  9. Sah DWY. Therapeutic potential of RNA interference for neurological disorders. Life Sci. 2006;79:1773–1780
  10. Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy—an overview. Lung Cancer. 2003;41:81–88
  11. Emilsson GM, Nakamura S, Roth A, Breaker RR. Ribozyme speed limits. RNA. 2003;9:907–918
  12. Doudna JA, Cech TR. The chemical repertoire of natural ribozymes. Nature. 2002;418:222–228
  13. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002;296:1000–1004
  14. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient Reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem. 2003;278:7108–7118
  15. Layzer JM, McCaffrey AP, Tanner AK, Huang ZAN, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10:766–771
  16. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41:1349–1356
  17. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–114
  18. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541–552
  19. Gallo M, Kretschmer-Kazemi Far R, Sczakiel G, Iribarren A. Activity and stability of hammerhead ribozymes containing 2′-C-methyluridine: a new RNA mimic. Chem Biodivers. 2005;2:198–204
  20. Hendry P, McCall M, Stewart T, Lockett T. Redesigned and chemically-modified hammerhead ribozymes with improved activity and serum stability. BMC Chem Biol. 2004;4:1
  21. Sall A, Liu Z, Zhang HM, Yuan J, Lim T, Su Y, et al. MicroRNAs-based therapeutic strategy for virally induced diseases. Curr Drug Discov Technol. 2008;5:49–58
  22. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102:5820–5825
  23. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther. 2005;12:618–633
  24. Gewirtz AM. RNA targeted therapeutics for hematologic malignancies. Blood Cells Mol Dis. 2007;38:117–119
  25. Rohl T, Kurreck J. RNA interference in pain research. J Neurochem. 2006;99:371–380
  26. Christoph T, Grunweller A, Mika J, Schafer MKH, Wade EJ, Weihe E, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun. 2006;350:238–243
  27. Hickerson RP, Smith FJD, Irwin Mclean WH, Landthaler M, Leube RE, Kaspar RL. SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann NY Acad Sci. 2006;1082:56–61
  28. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nature Rev Drug Discov. 2004;3:318–329
  29. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 2004;10:12–18
  30. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5:834–839
  31. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003;34:263–264
  32. Xu J, Li L, Hong J, Huang W. Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: evidence for non-synergetic cooperation. Cell Biol Int. 2007;31:88–91
  33. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644–670
  34. Li XZJ, Lu MQ, Yang Y, Xu C, Li H, Wang GS, et al. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch Surg. 2007;392:345–351
  35. Zhang XZX, Sun H, Feng B, Chen G, Vladau C, Li M, et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation. 2006;82:1728–1732
  36. Zender LKS. Suppression of apoptosis in the liver by systemic and local delivery of small-interfering RNAs. Methods Mol Biol. 2007;361:217–226
  37. Shin D, Kim SI, Kim M, Park M. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Res. 2006;119:146–153
  38. Hino T, Yokota T, Ito S, Nishina K, Kang YS, Mori S, et al. In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem Biophys Res Commun. 2006;340:263–267
  39. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet. 2005;54:3–20
  40. Koller E, Propp S, Murray H, Lima W, Bhat B, Prakash TP, et al. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res. 2006;34:4467–4476
  41. Nawrot B, Sipa K. Chemical and structural diversity of siRNA molecules. Curr Top Med Chem. 2006;6:913–925
  42. Kunisawa J, Masuda T, Katayama K, Yoshikawa T, Tsutsumi Y, Akashi M, et al. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release. 2005;105:344–353
  43. Moschos SA, Williams AE, Lindsay MA. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans. 2007;35:807–810
  44. Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev. 2007;59:134–140
  45. Song E, Zhu P, Lee S-K, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–717
  46. Vornlocher HP. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med. 2006;12:1–3
  47. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13:1222–1234
  48. Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng. 2007;97:909–921
  49. Fan Y, Xin X, Chen B, Ma X. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology. 2006;38:561–567
  50. Furset G, Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun. 2007;352:642–649
  51. Hagemann C, Meyer C, Stojic J, Eicker S, Gerngras S, Kuhnel S, et al. High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J Neurosci Methods. 2006;156:194–202
  52. Michaela M, Hana K, Radim B, Hana B. Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep. 2007;34:27–33
  53. Chen G, Dong Q, Zhang J, Fu F, Xu Z, Liang Q, et al. Knockdown of PLK1 mRNA by special siRNA. Yi Chuan. 2006;28:21–25
  54. Zhang M, Guller S, Huang Y. Method to enhance transfection efficiency of cell lines and placental fibroblasts. Placenta. 2008;28:779–782
  55. Xu RX, Tu YY, Jiang XD, Feng JN, Huang J. Apoptosis of glioma cell line U251 induced by small interfering RNA targeting survivin. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26:398–401[Chinese]
  56. Grayson ACR, Ma J, Putnam D. Kinetic and efficacy analysis of RNA interference in stably and transiently expressing cell lines. Mol Pharmaceutics. 2006;3:601–613
  57. LI GY, Fan B, Wu YZ, Wang XR, Wang YH, Wu JX. Inhibition of vascular endothelial growth factor gene expression by T7-siRNAs in cultured human retinal pigment epithelial cells. Chin Med J. 2005;118:567–573
  58. Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L, et al. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther. 2007;14:752–759
  59. Bejjani RA, Andrieu C, Bloquel C, Berdugo M, BenEzra D, Behar-Cohen F. Electrically assisted ocular gene therapy. Survey Ophthalmol. 2007;52:196–208
  60. Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands J, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett. 1996;389:225–228
  61. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev. 2007;59:141–152
  62. Sioud M. RNAi therapy: antibodies guide the way. Gene Ther. 2005;13:194–195
  63. Yutaka I, Kazunari T. Ligand-targeted delivery of therapeutic siRNA. Pharm Res. 2006;23:1631–1640
  64. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32:e149
  65. Cardoso A, Simões S, de Almeida L, Pelisek J, Culmsee C, Wagner E, et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med. 2007;9:170–183
  66. Choi JS, MacKay JA, Szoka FC. Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. Bioconjug Chem. 2003;14:420–429
  67. Shao K, Hou Q, Go M, Duan W, Cheung N, Feng S, et al. Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell Mol Life Sci. 2007;64:506–515
  68. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007—an update. J Gene Med. 2007;9:833–842
  69. Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun. 2003;312:1220–1225
  70. Bouxsein NF, McAllister CS, Ewert KK, Samuel CE, Safinya CR. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry. 2007;46:4785–4792
  71. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry. 2004;43:13348–13356
  72. Wang Y, Gao S, Ye W-H, Yoon HS, Yang Y-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006;5:791–796
  73. Kakizawa Y, Furukawa S, Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J Control Release. 2004;97:345–356
  74. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115:216–225
  75. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res. 2007;47:1202–1208
  76. Nedjma T, Jean-Rémi B, Ali T, Hind E, Hervé H, Andrei M, et al. Efficacy of siRNA nanocapsules targeted against the EWS–Fli1 oncogene in Ewing sarcoma. Pharm Res. 2006;23:892–900
  77. Lee H, Mok H, Lee S, Oh YK, Park TG. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119:245–252
  78. Segura T, Hubbell JA. Synthesis and in vitro characterization of an ABC triblock copolymer for siRNA delivery. Bioconjug Chem. 2007;18:736–745
  79. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A. 2005;102:12177–12182
  80. Svintradze DV, Mrevlishvili GM. Fiber molecular model of atelocollagen-small interfering RNA (siRNA) complex. Int J Biol Macromol. 2005;37:283–286
  81. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004;32:e109
  82. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Höbel S, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751–766
  83. Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans. 2007;35:44–46
  84. Vogel V, Lochmann D, Weyermann J, Mayer G, Tziatzios C, van den Broek JA, et al. Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release. 2005;103:99–111
  85. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol. 2006;133:9–29
  86. Ling B, Zhou Y, Feng D, Shen G, Gao T, Shi Y, et al. Down-regulation of EDAG expression by retrovirus-mediated small interfering RNA inhibits the growth and IL-8 production of leukemia cells. Oncol Rep. 2007;18:659–664
  87. Jeong Soon J, So Yeon K, Sang Bong L, Kyung Ok K, Joong Soo H, Young Moo L. Poly(ethylene glycol)/poly([epsilon]-caprolactone) diblock copolymeric nanoparticles for non-viral gene delivery: the role of charge group and molecular weight in particle formation, cytotoxicity and transfection. J Control Release. 2006;113:173–182
  88. Li L, Yang L, Scudiero DA, Miller SA, Yu ZX, Stukenberg PT, et al. Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther. 2007;14:814–827
  89. Fang C, Shi B, Pei Y-Y, Hong M-H, Wu J, Chen H-Z. In vivo tumor targeting of tumor necrosis factor-[alpha]-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27:27–36
  90. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377:159–169
  91. Zuhorn I, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem. 2002;277:18021–18028
  92. De Smedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res. 2000;17:113–126
  93. Akin A. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7:657–663
  94. Grayson AC, Doody A, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res. 2006;23:1868–1876
  95. Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev. 1998;32:139–152
  96. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137–172
  97. Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Res Suppl. 2005;49:17–18
  98. Hirsch-Lerner D, Zhang M, Eliyahu H, Ferrari ME, Wheeler CJ, Barenholz Y. Effect of “helper lipid” on lipoplex electrostatics. Biochim Biophys Acta. 2005;1714:71–84
  99. Zimmer A, Atmaca-Abdel A, Gilbert M, Werner D, Noe C. Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides. Eur J Pharm Biopharm. 1999;47:175–178
  100. Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N, Mixson AJ. Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect. 2007;20:77–86
  101. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004;12:461–466
  102. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–1007
  103. Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm. 2005;59:419–429
  104. Weyermann J, Lochmann D, Georgens C, Zimmer A. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: Cellular uptake and effect. Eur J Pharm Biopharm. 2005;59:431–438
  105. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000;60:249–271
  106. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol. 1995;49:807–838
  107. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 1997;11:615–623
  108. Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature. 1997;389:239–242
  109. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 2004;10:162–171
  110. Zhao L-J, Jian H, Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene. 2003;316:137–141
  111. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10:4239–4242
  112. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992;11:3053–3058[Erratum in: EMBO J. 1992;11:4249]
  113. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267
  114. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A. 1997;94:10319–10323
  115. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71:6641–6649
  116. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007;46:200–208
  117. Chiu Y-L, Ali A, Chu C-y, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004;11:1165–1175
  118. Berezhna SY, Supekova L, Supek F, Schultz PG, Deniz AA. siRNA in human cells selectively localizes to target RNA sites. Proc Natl Acad Sci U S A. 2006;103:7682–7687

 No conflict of interest was reported by the authors of this article.

PII: S1549-9634(08)00082-8

doi: 10.1016/j.nano.2008.06.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 8-20 , March 2009

Article Tools

* Image Usage & Resolution